147 related articles for article (PubMed ID: 23035722)
1. Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11.
Feng Y; Lau E; Scortegagna M; Ruller C; De SK; Barile E; Krajewski S; Aza-Blanc P; Williams R; Pinkerton AB; Jackson M; Chin L; Pellecchia M; Bosenberg M; Ronai ZA
Pigment Cell Melanoma Res; 2013 Jan; 26(1):136-42. PubMed ID: 23035722
[TBL] [Abstract][Full Text] [Related]
2. Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways.
Feng Y; Barile E; De SK; Stebbins JL; Cortez A; Aza-Blanc P; Villanueva J; Heryln M; Krajewski S; Pellecchia M; Ronai ZA; Chiang GG
Pigment Cell Melanoma Res; 2011 Aug; 24(4):703-13. PubMed ID: 21592316
[TBL] [Abstract][Full Text] [Related]
3. BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.
Gaitonde S; De SK; Tcherpakov M; Dewing A; Yuan H; Riel-Mehan M; Krajewski S; Robertson G; Pellecchia M; Ronai Z
Pigment Cell Melanoma Res; 2009 Apr; 22(2):187-95. PubMed ID: 19175524
[TBL] [Abstract][Full Text] [Related]
4. BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt.
Pal I; Sarkar S; Rajput S; Dey KK; Chakraborty S; Dash R; Das SK; Sarkar D; Barile E; De SK; Pellecchia M; Fisher PB; Mandal M
Br J Cancer; 2014 Jul; 111(1):101-11. PubMed ID: 24892445
[TBL] [Abstract][Full Text] [Related]
5. High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma.
Jonsson A; Tuominen R; Grafström E; Hansson J; Egyhazi S
J Invest Dermatol; 2010 Dec; 130(12):2809-17. PubMed ID: 20703244
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
7. Blockade of autophagy enhances proapoptotic potential of BI-69A11, a novel Akt inhibitor, in colon carcinoma.
Pal I; Parida S; Prashanth Kumar BN; Banik P; Kumar Dey K; Chakraborty S; Bhutia SK; Mandal M
Eur J Pharmacol; 2015 Oct; 765():217-27. PubMed ID: 26306675
[TBL] [Abstract][Full Text] [Related]
8. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
[TBL] [Abstract][Full Text] [Related]
9. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
10. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.
Jovanovic B; Egyhazi S; Eskandarpour M; Ghiorzo P; Palmer JM; Bianchi Scarrà G; Hayward NK; Hansson J
J Invest Dermatol; 2010 Feb; 130(2):618-20. PubMed ID: 19759551
[No Abstract] [Full Text] [Related]
11. Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice.
Yang G; Curley D; Bosenberg MW; Tsao H
Cancer Res; 2007 Jun; 67(12):5649-57. PubMed ID: 17575131
[TBL] [Abstract][Full Text] [Related]
12. Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
Krisp C; Parker R; Pascovici D; Hayward NK; Wilmott JS; Thompson JF; Mann GJ; Long GV; Scolyer RA; Molloy MP
Br J Cancer; 2018 Sep; 119(6):713-723. PubMed ID: 30116025
[TBL] [Abstract][Full Text] [Related]
13. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
14. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
15. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
17. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
18. C57BL/6 congenic mouse NRAS
Petit V; Raymond J; Alberti C; Pouteaux M; Gallagher SJ; Nguyen MQ; Aplin AE; Delmas V; Larue L
Pigment Cell Melanoma Res; 2019 Nov; 32(6):829-841. PubMed ID: 31251472
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.
Daniotti M; Ferrari A; Frigerio S; Casieri P; Miselli F; Zucca E; Collini P; Della Torre G; Manoukian S; Peissel B; Bono A; Santinami M; Parmiani G; Rivoltini L; Pilotti S; Rodolfo M
J Invest Dermatol; 2009 Jul; 129(7):1759-68. PubMed ID: 19158841
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
